Furan, tetrahydro-2,4-dimethyl-, cis- | 39168-01-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: Furan, tetrahydro-2,4-dimethyl-, cis-
• 英文别名: (2S,4R)-2,4-dimethyloxolane
• CAS: 39168-01-9
• 化学式: C₆H₁₂O
• 分子量: 100.16
• InChiKey: QMGLMRPHOITLSN-RITPCOANSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (2S,4S)-2,4-dimethyloxolane 、 Furan, tetrahydro-2,4-dimethyl-, cis- 、 1,3-丙二硫醇 以58%的产率得到
  参考文献：
  名称：

  HIRAI, YOSHIRO;YOKOTA, KATSUYUKI;SAKAI, HIROSHI;, YAMAZAKI TAKAO;MOMOSE, +, HETEROCYCLES, 29,(1989) N0, C. 1865-1869

  摘要：

  DOI：
• 作为产物：
  描述：

  S-环氧丙烷 、 Dilithium;prop-1-ene-1,1-diolate 生成 Furan, tetrahydro-2,4-dimethyl-, cis-
  参考文献：
  名称：

  HIRAI, YOSHIRO;YOKOTA, KATSUYUKI;SAKAI, HIROSHI;, YAMAZAKI TAKAO;MOMOSE, +, HETEROCYCLES, 29,(1989) N0, C. 1865-1869

  摘要：

  DOI：

文献信息

• HIRAI, YOSHIRO;YOKOTA, KATSUYUKI;SAKAI, HIROSHI;, YAMAZAKI TAKAO;MOMOSE, +, HETEROCYCLES, 29,(1989) N0, C. 1865-1869
  作者：HIRAI, YOSHIRO、YOKOTA, KATSUYUKI、SAKAI, HIROSHI、, YAMAZAKI TAKAO、MOMOSE, +

  DOI：——

  日期：——
• WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF
  申请人：Suzhou Yunxuan Yiyao Keji Youxian Gongsi

  公开号：US20200048223A1

  公开（公告）日：2020-02-13

  Inhibitors of Wnt signaling pathway with structures of Formula I are disclosed, together with their pharmaceutical salts. Applications of compounds of Formula I in inhibiting or modulating the Wnt signaling pathway are also disclosed. Compounds of Formula I can treat disorders caused by aberrant activation of the Wnt signaling pathway.
• [EN] WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF<br/>[FR] INHIBITEURS DE LA VOIE DE SIGNALISATION WNT ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：ZHANG XIAOHU

  公开号：WO2017062688A1

  公开（公告）日：2017-04-13

  Inhibitors of Wnt signaling pathway with structures of Formula I are disclosed, together with their pharmaceutical salts. Applications of compounds of Formula I in inhibiting or modulating the Wnt signaling pathway are also disclosed. Compounds of Formula I can treat disorders caused by aberrant activation of the Wnt signaling pathway.